The Latest Breaking News from Castle Biosciences

Castle Biosciences's Return On Capital Employed Insights

Castle Biosciences (NASDAQ:CSTL) brought in sales totaling $26.85 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 282.94%, resulting in a loss of $24.62 million.

Benzinga · Jun 6, 2022

Castle Biosciences snaps up San Diego's AltheaDx to push precision medicine into mental health

San Diego startup AltheaDx, which developed a molecular test designed to guide therapy for depression and anxiety based on a patient's genetics, is being acquired for $65 million in stock and cash.

Tribune News Service · Apr 6, 2022

Castle Biosciences Adds Mental Health Testing Solutions Via AltheaDx Acquisition

Castle Biosciences Inc (NASDAQ: CSTL) has agreed to acquire AltheaDx Inc, a commercial-stage molecular diagnostics company, 

Benzinga · Apr 5, 2022